Abstract: An improved process can be used for the production of methacrylates, in particular methacrylic acid and/or methyl methacrylate (MMA). Specific embodiments of this process can be used for the safe and efficient production of these products from C-4-based raw materials, in particular those based on isobutylene or tert-butanol as raw materials. With this novel process, it is possible to operate such processes for a longer period of time without any safety or cleaning related shutdowns. This makes it possible to carry out such processes as simple, economic, and environmentally friendly as possible.

Abstract: The present invention relates to a 6-hydroxy-3-hexenyl alkoxymethyl ether compound of the following general formula (1): HOCH2CH2CH?CHCH2CH2OCH2OCH2R? (1), R1 representing a hydrogen atom, an n-alkyl group having 1 to 9 carbon atoms, or a phenyl group; and also relates to a process for preparing a 3,13-octadecadien-1-ol compound of the following formula (6): CH3(CH2)3CH?CH(CH2)8CH?CHCH2CH2OH (6) from the 6-hydroxy-3-hexenyl alkoxymethyl ether compound (1).

Abstract: The embodiments provide processes for preparing a diisocyanate composition and an optical lens, which are excellent in yield and quality with mitigated environmental problems by using a solid triphosgene composition instead of phosgene gas in the process of preparing a diisocyanate from a diamine through a hydrochloride thereof and by controlling the content of a decomposition product in a triphosgene composition, the b* value according to CIE color coordinate of the triphosgene composition in an organic solvent, or the content of water in the triphosgene.

Abstract: The invention relates to triesters of cyclohexanetripropionic acid, preparation thereof and use thereof as plasticizers for polymers wherein examples of the triester of cyclohexanetripropionic acid include tri(nbutyl) cyclohexane-1,2,4-tripropionate, tri(methylpropyl) cyclohexane-1,2,4-tripropionate, tri(npentyl) cyclohexane-1,2,4-tripropionate, tri(isopentyl) cyclohexane-1,2,4-tripropionate, tri(2-methylbutyl) cyclohexane-1,2,4-tripropionate, tri(3-methylbutyl) cyclohexane-1,2,4-tripropionate, tri(nhexyl) cyclohexane-1,2,4-tripropionate, tri(isohexyl) cyclohexane-1,2,4-tripropionate, tri(nheptyl) cyclohexane-1,2,4-tripropionate, tri(isoheptyl) cyclohexane-1,2,4-tripropionate, tri(noctyl) cyclohexane-1,2,4-tripropionate, tri(isooctyl) cyclohexane-1,2,4-tripropionate, tri(2-ethylhexyl) cyclohexane-1,2,4-tripropionate, tri(nnonyl) cyclohexane-1,2,4-tripropionate, tri(isononyl) cyclohexane-1,2,4-tripropionate, tri(ndecyl) cyclohexane-1,2,4-tripropionate, tri(isodecyl) cyclohexane-1,2,4-tripropionate, and tri(2-p

Abstract: The present invention discloses a method for directly constructing highly optically active tetrasubstituted allenic acid compounds, i.e., a one-step process for directly constructing highly optically active axially chiral tetrasubstituted allenic acid compounds by using tertiary propargyl alcohol, carbon monoxide and water as reactants in an organic solvent in the presence of palladium catalyst, chiral diphosphine ligand, monophosphine ligand and organic phosphoric acid. The method of the present invention has the following advantages: operations are simple, raw materials and reagents are readily available, the reaction conditions are mild, the substrate has high universality, the functional group has good compatibility, and the reaction has high enantioselectivity (90%˜>99% ee).

Abstract: Disclosed are methods for preparing compounds of Formula 1 and 1A. The first method utilizes a benzyl carbamate amine protecting group and an intermediate of Formula 4. The second method utilizes a tert-butyl carbamate amine protecting group and an intermediate of Formula 7. The third method utilizes a dibenzyl amine protecting group. Also disclosed is a compound, phenylmethyl N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]carbamate (a compound of Formula 4). Further disclosed is a method for preparing a compound of Formula 14 from a compound of Formula 15 and a compound of Formula 1 or 1A.

Abstract: The present invention relates to high doses of macitentan (INN), i.e. propylsulfamic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof, or of aprocitentan, for use in the treatment and/or prevention of chronic thromboembolic pulmonary hypertension (CTEPH). Moreover, the present invention relates to the use of high doses of macitentan or of aprocitentan for the manufacture of a medicament for the treatment and/or prevention of CTEPH, as well as to a method for the treatment and/or prevention of CTEPH comprising administering high doses of macitentan or of aprocitentan to a patient.

Abstract: In methods for preparing an alkyl carboxylic acid ester according to embodiments of the present invention, a first reaction product is produced by reaction of a carboxylic acid stream and a first alcohol stream in a preliminary reactor. A second reaction product is produced by at least partially removing alcohol and water from the first reaction product. The second reaction product is esterified by reaction with a second alcohol stream in a main reactor. An alkyl carboxylic acid ester is recovered from the main reactor.

Abstract: Proposed is a catalyst complex having high activity for carbon dioxide conversion reaction that converts carbon dioxide to useful compounds through reaction of carbon dioxide and hydrocarbon containing at least one hydroxyl group, and a carbon dioxide conversion process using the same, wherein the catalyst complex includes, as an active metal in the catalyst complex, at least one of noble metals and at least one of transition metals other than noble metals, thereby having high activity for the carbon dioxide conversion reaction.

Abstract: Provided is a compound represented by Formula (VI) for preparing lisdexamphetamine or a salt thereof. Also provided is a method for preparing lisdexamfetamine or a salt thereof including performing reduction and debenzylation of the compound represented by Formula (VI) by hydrogenation.

Abstract: The invention discloses a c-Met regulatory composition and its method for treating liver disease, a main component of the c-Met regulatory composition comprises Antrodin A and/or DMB (4,7-Dimethoxy-5-methyl-1,3-benzodioxole) capable of effectively regulating gene expression related to cell regeneration and cytothesis in hepatic cells, such as c-Met, Notch, etc., to achieve efficacies of repairing damaged hepatic cells and promoting hepatocyte regeneration.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Abstract: Methods for the preparation of bio-based malonic acid and diester derivatives of malonic acid are provided. For example, a dialkyl malonate may be prepared by the steps of (i) separating calcium malonate crystals from a fermentation broth; (ii) obtaining dissolved malonic acid; (iii) crystallizing the dissolved malonic acid; and (iv) performing esterification to obtain the dialkyl malonate. The disclosed methods produce diester derivatives of malonic acid with fewer impurities, which is useful for many industrial processes. The diester derivatives of malonic acid can be purified from existing sources of malonic acid, or from malonic acid made from a renewable carbon source.

Abstract: A process for process for preparing 6-isopropenyl-3-methyl-9-decenyl acetate of the following formula (3), wherein Ac represents an acetyl group, the process comprising steps of: preparing a nucleophilic reagent, 5-isopropenyl-2-methyl-8-nonenyl compound, of the following general formula (1): wherein M1 represents Li, MgZ1, ZnZ1, Cu, CuZ1, or CuLiZ1, wherein Z1 represents a halogen atom or a 5-isopropenyl-2-methyl-8-nonenyl group, from a 5-isopropenyl-2-methyl-8-nonenyl halide compound of the following general formula (4): wherein X1 represents a halogen atom; subjecting the nucleophilic reagent (1), 5-isopropenyl-2-methyl-8-nonenyl compound, to an addition reaction with at least one electrophilic reagent selected from the group consisting of formaldehyde, paraformaldehyde, and 1,3,5-trioxane, followed by a hydrolysis reaction to form 6-isopropenyl-3-methyl-9-decenol of the following formula (2); and acetylating 6-isopropenyl-3-methyl-9-decenol (2) to form 6-isopropenyl-3-methyl-9-decenyl acetate (3).

Abstract: A method for manufacturing an isocyanate compound represented by formula (2) (2) wherein R1 represents a methyl group, an ethyl group, a cyclopropyl group, a chlorine atom, a bromine atom, or a methoxy group; and R2 represents an alkyl group having 1 to 6 carbon atoms, comprising reacting an aniline compound represented by formula (1) (1) wherein R1 and R2 are defined as above with a phosgene compound at a temperature of from 40° C. to the boiling point of the inert solvent in at least one kind of inert solvent.

Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.

Abstract: A process for preparing dialkyl terephalate comprising the following steps:—i) providing furan-2,5-dicarboxylate; ii) esterifying the furan-2,5-dicarboxylate with alcohol to form furan-2,5-carboxylic acid dialkyl ester; iii) reacting the furan-2,5-carboxylic acid dialkyl ester with ethylene under Diels Alder conditions, elevated temperature and pressure and in the presence of a catalyst such that dialkyl terephthalate is produced; wherein the Diels-Alder reaction is free from solvent; wherein the catalyst comprises a clay comprising metal ions and having Lewis acidity.

Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, R20, X, Y, Q and Z have defined meanings.

Abstract: Methods for the production of 2,4-dihydroxybutyrate (2,4-DHB) from erythrose and other four-carbon sugars are disclosed. The improved methods facilitate the production of 2,4-DHB that is a precursor for biorenewable and animal nutrition chemicals among others.

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.